Atomoxetine (the active ingredient in Strattera®) is produced by a number of manufacturers, each of which has its own licensed manufacturing sites that meet Good Manufacturing Practice (GMP) standards. Because the drug is available both as a branded product (Strattera) and as a variety of generics, the “manufacturing location” can vary depending on who’s making the particular batch.
| Product | Manufacturer | Typical manufacturing sites (as of the latest public information) |
|---------|--------------|--------------------------------------------------------------------|
| Strattera® (brand‑name) | Eli Lilly & Co. | Eli Lilly’s U.S. manufacturing facilities (e.g., in the Midwest) – the exact plant is proprietary, but the U.S. site is the primary source for the U.S. market. Eli Lilly also has production plants in Canada and Europe that can supply Strattera for international markets. |
| Generic atomoxetine | Teva Pharmaceuticals | U.S. facilities in New Mexico and Texas; U.K. plant in Bristol; Spain and other European sites. (Teva’s plant in New Zealand is used for other APIs, not specifically atomoxetine.) |
| | Mylan (now part of Viatris) | U.S. plants in Kansas, Ohio, and other states; European facilities in Germany, Belgium, etc. |
| | Sandoz (Novartis) | U.S. plant in New York; European sites in the Netherlands, Germany, and Switzerland. |
| | Other generic makers | Companies such as Actavis (now part of Allergan), Cipla, and many Asian manufacturers (e.g., China, India, Thailand) each run GMP‑compliant facilities for atomoxetine production. |
Key points to keep in mind
1. GMP‑Certified Sites – Every site that produces atomoxetine is required to meet U.S. FDA or EMA GMP standards. The specific plant can change over time as companies update their manufacturing portfolios.
2. API Source – The active pharmaceutical ingredient (atomoxetine base) is often supplied by dedicated API manufacturers located in China, India, or other countries. The finished drug product (capsules or tablets) is then formulated and filled at a final‑assembly plant.
3. Regulatory Transparency – The FDA’s drug label (for Strattera) lists the “Manufacturer” and “Address of Manufacturer” for each lot, but these addresses can shift. For generics, the manufacturer’s address is usually listed in the package insert or on the product label.
4. Geographic Diversity – Because atomoxetine is a globally‑available medication, there is no single “home” for the drug. The U.S., Canada, the EU, and many other regions all have licensed production sites.
If you need the exact address for a particular lot (e.g., for a pharmacy’s trace‑back or for a clinical trial), the most reliable source is the drug’s FDA label or the manufacturer’s website. For most patients, the key point is that atomoxetine is manufactured in GMP‑approved facilities around the world and is subject to the same quality controls as all prescription medications.